DDInter1863 DDInter1016
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Triclabendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triclabendazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Triclabendazole may lead to a major life threatening interaction when taken with Vemurafenib
Triclabendazole may lead to a major life threatening interaction when taken with Ivosidenib